Previous close | 0.2350 |
Open | 0.2350 |
Bid | 0.2250 x 1582700 |
Ask | 0.2350 x 3535900 |
Day's range | 0.2250 - 0.2350 |
52-week range | 0.1050 - 0.2400 |
Volume | |
Avg. volume | 159,108 |
Market cap | 40.417M |
Beta (5Y monthly) | 0.78 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0900 |
Earnings date | 23 Jul 2024 - 28 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU).
Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD).
Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has completed initial analysis of wound surface area in the first 16 patients in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU), up to the 10-week follow-up time point.